CliffBio
small molecule

KYPROLIS

CARFILZOMIB

Loss of exclusivityOctober 2041latest FDA-listed patent expiry
CompanyONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC

Drug detail

Brand nameKYPROLIS
Active ingredientCARFILZOMIB
Strength30MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2016
Marketing statusRX

Listed patents

PatentExpiresType
12636340*PEDOctober 2041—
12636340April 2041use U-4551
9493582*PEDAugust 2033—
9493582February 2033product
RE47954*PEDApril 2030—
RE47954October 2029use U-3449
7737112*PEDJune 2028—
7737112December 2027product
7417042*PEDJanuary 2027—
7417042July 2026substance, product

Regulatory exclusivity

CodeExpires
PEDNovember 2028
M-14May 2028

More from ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

KYPROLIS patent cliff — loss of exclusivity October 2041 | CliffBio